

Protein-Protein Interactions 2016

Monday 5 - Tuesday 6 December 2016, SCI, London, UK

Organised by SCI's Fine Chemicals Group and RSC's BMCS in association with PPI-Net

Synopsis

Virtually all vital cellular processes are controlled by protein-protein interactions (PPIs) including gene expression, proliferation, intracellular communication and apoptosis. Thus, understanding and manipulating PPIs represents a key objective in being able to understand healthy and disease biology. Achieving this goal will lead to probes of cell signalling pathways or, systems biology and next generation molecular therapeutics. However, to date, only a few PPIs have been the subject of a drug discovery initiative by the pharmaceutical industry.

Owing to the potential opportunities that being able to modulate PPIs would bring, the past decade has seen this field gain increasing scientific interest, and stimulated significant academic and industrial innovation. This meeting will address recent advances in the characterisation and identification of new PPI inhibitors. Topics will include: *in silico* assessment of PPI druggability, assay screening technologies for PPIs, structural biology approaches and fragment-based drug design. Speakers from industry and academia will describe strategies for addressing these challenges whilst showcasing the opportunity for creativity and innovation.

Attendees

The event is aimed at all scientists (students, post-docs, academics, industrialists) engaged in PPI research, alongside those interested in finding out more about this topic. The meeting programme will appeal to chemists, biologists and the wider drug-discovery community. SCI Members can claim CPD points for attending this conference.

Sponsorship

To enquire about sponsorship opportunities, please contact **clarice.williams@soci.org** for further information and costs.

Registration

Book today! www.soci.org/events

GB£200. . . . . SCI/RSC Member
GB£40. . . . . SCI/RSC Student Member
GB£260. . . . . Non Member

The CPD Standards Office
CPD PROVIDER: 41057
2016 - 2018
www.cpdstandards.com

Accredited cpd Event

#PPI2016
@SCIUpdate

SCI
where science meets business

Programme

Monday 5 December

09.30 Plenary talk
Cooperativity in multiprotein assemblies over space and time: implications for cell signalling and druggability
Sir Tom Blundell, University of Cambridge, UK

10.30
Targeting protein-protein interactions in the brain
Prof Hans Michael Maric, University of Copenhagen, Denmark

11.00 Refreshments, poster and exhibition viewing

11.30
Targeting aggregating proteins in drug discovery
Dr Lewis Vidler, Eli Lilly & Co, UK

12.00
Using the kinase ATP binding site to inhibit PPIs
Prof Richard Bayliss, University of Leeds, UK

12.30 Lunch, poster and exhibition viewing

13.30
Folded fragment approach for target-directed development of protein-protein interaction inhibitors
Prof Dr Mr Tamás Martinek, University of Szeged, Hungary

14.00
Characterising PPI interfaces and assessing druggability using mixed-solvent simulations
Dr Davide Branduardi, Schrodinger, UK

14.30
Discovery and characterization of small molecule fragments that bind and inhibit the ubiquitin specific protease 7 (USP7)
Dr Paola Di Lello, Genentech, USA

15.00 Refreshments, poster and exhibition viewing

15.30
Inhibiting PPIs: a structural biologist's perspective
Dr Thomas Edwards, University of Leeds, UK

16.00 Flash poster presentations

16.30 Wine reception and poster viewing

19.00 Conference Dinner

Organising Committee

- Dr Nicola Chessum, SCI/ The Institute of Cancer Research
- Dr Stephen East, SCI/ Evotec (UK) Ltd
- Dr Jason Tierney, SCI/ Charles River
- Prof Simon Ward, RSC BMCS/ University of Sussex
- Prof Andrew Wilson, PPI-Net/ University of Leeds

Tuesday 6 December

09.30 Plenary talk
Discovery of Mcl-1 inhibitors using fragment-based methods and structure-based design
Prof Steve Fesik, Vanderbilt University Medical Centre, USA

10.30
ProMs: A construction kit for small-molecule inhibitors of protein-protein interactions involving proline-rich motifs
Prof Dr Hans-Guenther Schmalz, University of Cologne, Germany

11.00 Refreshments, poster and exhibition viewing

11.30
Highly potent cell-penetrant inhibitors of the KEAP1-NRF2 protein-protein interaction via X-Ray fragment screening
Dr Tom Heightman, Astex Pharmaceuticals, UK

12.00
The discovery of NVP-HDM201: identification of a next generation HDM2 inhibitor with superior characteristics
Dr Andrea Vaupel, Novartis, Switzerland

12.30 Lunch, poster and exhibition viewing

13.30
Protein-fragment complementation and semi-rational design: engineering specific antagonists of protein-protein interactions
Dr Jody Mason, University of Bath, UK

14.00
Small molecule inhibition of PCSK9-LDL receptor binding: a summit too high?
Dr Kim McClure, Pfizer, USA

14.30
Targeting the SCL-LMO2 interaction: a structure-guided approach to T-ALL drug discovery
Dr Leanne Harris, University of Sussex, UK

15.00 Refreshments, poster and exhibition viewing

15.30
Inhibition of FGFR2 oncogenic activity by its C-terminal tail
Dr Chi-Chuan Lin, University of Leeds, UK

16.00
Antibody-enabled small molecule drug discovery
Dr Alastair Lawson, UCB, UK

16.30
Talk title to be announced
Dr Jon Winter-Holt

17.00 Closing remarks

17.30 Meeting close

#PPI2016
@SCIUpdate

AstraZeneca

ROYAL SOCIETY OF CHEMISTRY | BIOLOGICAL AND MEDICINAL CHEMISTRY SECTOR

PPI-Net
Protein-Protein Interactions Network

SCI
where science meets business